AXGN vs ORGO
AXGN: Axogen is the market leader in regenerative medical technologies dedicated to restoring quality of life for patients through innovative peripheral nerve repair solutions. ORGO: Organogenesis is a tissue-engineered wound care and surgical reconstruction company whose financial health depends critically on Medicare reimbursement rates and FDA regulatory compliance.
Side-by-side fundamentals
| Metric | AXGN | ORGO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $39.37 | $2.47 | |
| Market cap as of 2026-07-23 | $2.1B | $311M | |
| P/E as of 2026-07-23 | n/a | 114.52 | |
| PEG as of 2026-07-23 | -0.22 | -2.62 | ORGO lower |
| Net margin as of 2026-07-23 | -13.2% | +0.5% | ORGO higher |
| Gross margin as of 2026-07-23 | +75.0% | +72.9% | AXGN higher |
| Operating margin as of 2026-07-23 | -10.9% | +0.5% | ORGO higher |
| ROE as of 2026-07-23 | -20.7% | +0.7% | ORGO higher |
| ROA as of 2026-07-23 | -13.5% | +0.5% | ORGO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.03 | AXGN lower |
| Revenue growth (YoY) as of 2026-07-23 | +22.4% | +12.2% | AXGN higher |
| Revenue CAGR (3y) SEC XBRL | +17.6% | +7.8% | AXGN higher |
| Beta as of 2026-07-23 | 1.15 | 1.34 | |
| 1-year return as of 2026-07-22 close | +246.8% | -48.8% | AXGN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.